Tvardi Therapeutics, Inc. (TVRD) return on equity (ROE)

Return on equity · fiscal 2025
-87.0%

Tvardi Therapeutics, Inc. (TVRD) earned a return on equity of -87.0% in fiscal 2025 (the year ended December 31, 2025). Figures as of 18 Nov 2026, 03:17 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-87.0%
Highest on record
3.4%fiscal 2020
Lowest on record
-112.9%fiscal 2016
Fiscal years on record
92014–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Tvardi Therapeutics, Inc. return on equity (ROE), in more detail

Across the 9 fiscal years on record (2014–2025), the highest was 3.4% in fiscal 2020 and the lowest -112.9% in fiscal 2016. The fiscal 2025 figure is higher than in 13% of the 8 earlier fiscal years on record, whose median is -47.1%.

History · 9 fiscal years

Return on equity by fiscal year

Tvardi Therapeutics, Inc. return on equity (ROE), year by year

Tvardi Therapeutics, Inc. (TVRD) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-87.0%—
2021-38.9% 42.2 pts down
20203.4% 60.3 pts up
2019-57.0% 1.6 pts down
2018-55.4% 11.6 pts up
2017-67.0% 45.9 pts up
2016-112.9% 89.4 pts down
2015-23.5% 10.8 pts up
2014-34.3%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on TVRD

Tvardi Therapeutics, Inc., figure by figure

Tvardi Therapeutics, Inc. (TVRD) overview: price, valuation and scorecard

Tvardi Therapeutics, Inc. return on equity (ROE): questions and answers

What is Tvardi Therapeutics, Inc.'s return on equity?

Tvardi Therapeutics, Inc. (TVRD) earned a return on equity of -87.0% in fiscal 2025 (the year ended December 31, 2025).

Is Tvardi Therapeutics, Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 13% of the 8 earlier fiscal years on record, whose median is -47.1%.

What are the highest and lowest return on equity figures on record for Tvardi Therapeutics, Inc.?

Across the 9 fiscal years on record (2014–2025), the highest was 3.4% in fiscal 2020 and the lowest -112.9% in fiscal 2016.

How is Tvardi Therapeutics, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Tvardi Therapeutics, Inc. (TVRD) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/TVRD/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.